Drugs that spare the kidney
Not every anti-cancer drug is a nephrotoxin. These 20 agents carry little to no direct renal toxicity — useful to know when choosing therapy for a patient who already has chronic kidney disease.
Low direct nephrotoxicity is not the same as no renal considerations. Several of these still need dose adjustment for clearance, can shift electrolytes, or drive indirect prerenal injury through diarrhea, vomiting or tumor lysis. The caveat on each card still matters. Not medical advice.
Taxanes
Hepatically metabolized microtubule stabilizers — no renal dose adjustment and no characteristic renal lesion.
Paclitaxel
Taxol · Taxane
Hepatic (CYP) metabolism and biliary excretion; no renal dose adjustment.
Caveat Vehicle (Cremophor) hypersensitivity; neuropathy.
Docetaxel
Taxotere · Taxane
Hepatically cleared; kidney function largely irrelevant to dosing.
Caveat Fluid retention; monitor hepatic function.
Nab-paclitaxel
Abraxane · Taxane (albumin-bound)
Albumin-bound paclitaxel; no renal clearance dependence.
Caveat Neuropathy, myelosuppression.
Anthracyclines
The dose-limiting toxicity is the heart, not the kidney — no renal adjustment required.
Doxorubicin
Adriamycin · Anthracycline
Hepatobiliary clearance; clinically non-nephrotoxic.
Caveat Cumulative cardiomyopathy (the real ceiling); a classic experimental podocyte model only.
Liposomal doxorubicin
Doxil · Anthracycline
Same renal-sparing profile with altered pharmacokinetics.
Caveat Hand-foot syndrome.
Epirubicin
Ellence · Anthracycline
Hepatic clearance; no characteristic renal lesion.
Caveat Cardiotoxicity; tumor lysis with bulky disease.
Hormonal therapy
Endocrine agents are essentially non-nephrotoxic; their renal footprint is indirect at most.
Tamoxifen
Nolvadex · SERM
No direct renal toxicity.
Caveat VTE risk; rare hypercalcemia flare / SIADH.
Anastrozole
Arimidex · Aromatase inhibitor
Minimal renal handling; no dose adjustment in renal impairment.
Caveat Bone loss, arthralgia.
Letrozole
Femara · Aromatase inhibitor
Renally well tolerated.
Caveat Bone loss, hyperlipidemia.
Exemestane
Aromasin · Aromatase inhibitor
No meaningful nephrotoxicity.
Caveat Bone loss.
Fulvestrant
Faslodex · Selective ER degrader
Intramuscular depot; no renal toxicity.
Caveat Injection-site reactions.
Bicalutamide
Casodex · Anti-androgen
No direct renal injury.
Caveat Hepatotoxicity (monitor LFTs).
HER2 antibodies
The naked HER2 monoclonals spare the kidney — and, unlike anti-EGFR antibodies, they do NOT waste magnesium. Hypomagnesemia is an anti-EGFR (ERBB1 → EGF/TRPM6) effect; HER2 is the distinct ERBB2 receptor. Only the dual/pan-HER TKIs (lapatinib, neratinib, afatinib) that also hit EGFR cause Mg wasting.
Trastuzumab
Herceptin · Anti-HER2 antibody
Antibody cleared by the reticuloendothelial system; not nephrotoxic and no renal Mg wasting (that's anti-EGFR, not anti-HER2).
Caveat Cardiotoxicity (LVEF monitoring). Contrast with T-DM1 / T-DXd, which do carry renal signals.
Pertuzumab
Perjeta · Anti-HER2 antibody
No renal clearance dependence, no characteristic renal lesion, and no TRPM6-mediated magnesium wasting.
Caveat Cardiotoxicity; diarrhea.
Other cytotoxics & agents
Agents whose principal toxicity falls on other organs, leaving the kidney comparatively untouched.
5-Fluorouracil
Adrucil · Antimetabolite
Generally renally well tolerated as a single agent.
Caveat Rare TMA when combined with mitomycin; mucositis, cardiotoxicity.
Vinorelbine
Navelbine · Vinca alkaloid
Hepatic metabolism; low direct renal toxicity.
Caveat Rare SIADH; neuropathy, myelosuppression.
Bleomycin
Blenoxane · Antitumor antibiotic
Renal effect minimal; dose-adjust for clearance.
Caveat Pulmonary fibrosis is the dose-limiting toxicity.
Eribulin
Halaven · Microtubule inhibitor
No characteristic renal lesion.
Caveat Reduced clearance in renal impairment — adjust dose; neuropathy.
Etoposide
Etopophos · Topoisomerase II inhibitor
No direct tubular or glomerular toxicity.
Caveat Partly renally cleared — dose-adjust for CrCl; tumor lysis.
Irinotecan
Camptosar · Topoisomerase I inhibitor
Hepatic (UGT1A1) metabolism; no direct renal lesion.
Caveat Severe diarrhea can cause INDIRECT prerenal AKI.